Orexo develops a nasal adrenaline medication based on the novel amorphOXTM platform

UPPSALA, Sweden, Dec. 2, 2021 /PRNewswire/ — Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces it has initiated a new pharmaceutical development project, OX640, a nasal adrenaline product for the emergency treatment of allergic reactions. Adrenaline is commonly used for the…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.